The ALSFRSr predicts survival time in an ALS clinic population

Neurology

Volumn 64, Issue 1, 2005, Pages 38-43

  Kaufmann, P ^a,c   Levy, G ^b   Thompson, J L P ^b   DelBene, M L ^a   Battista, V ^a   Gordon, P H ^a   Rowland, L P ^a   Levin, B ^b   Mitsumoto, H ^a  

^a Columbia University ^*  (United States)

^b NONE   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENDER; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SURVIVAL RATE; SURVIVAL TIME; TRACHEOSTOMY; VITAL CAPACITY;

EID: 8844287033     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148648.38313.64     Document Type: Article

References (30)

1. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Selerosis/Riluzole Study Group II. Lancet 1996;347:1425-1431.
2. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999;52:1427-1433.
3. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
4. Bensimon G, Laeomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
5. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996;46:1244-1249.
6. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383-1388.
7. Miller RG, Moore DH, 2nd, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
8. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
9. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-1630.
10. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-586.
11. Shefner JM, Cudkowicz ME, Schoenfeld D, et al, and the NEALS Consortium. Clinical trial of creatine in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl):28, C31.
12. Brooks BR. Functional scales: summary. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3(suppl 1):S13-18.
13. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol 1996;53:141-147.
14. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
15. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997;152 suppl 1:S1-9.
16. Moore DH, Miller RG, WALS Study Group, ALS CARE Study Group. ALSFRS as a measure of disease progression and survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl 1):42, C50.
17. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz CE. Functional outcome measures as a clinical trial endpoint in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl 1):42, C51.
18. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709-714.
19. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994;124 suppl:96-107.
20. Cox DR. Regression models and life tables. J R Statist Soc B 1972;34:187-220.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:547-481.
22. Turner M, Al-Chalabi A. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:2012-2013; author reply 2013.
23. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
24. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:15-21.
25. Cedarbaum JM, Stambler N. Disease status and use of ventilatory support by ALS patients. BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:19-22.
26. Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 1999;169:118-125.
27. Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:177-185.
28. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996-2000. J Neurol 2003;250:473-479.
29. Bruvjn LI, Trotti D, Kristal BS, et al. Pre-clinical trials of three FDA-approved compounds in a mouse model of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl 1):76, C96.
30. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. Hoboken, NJ; Wiley Interscience, 2003.